Abstract:Loss-of-function mutations in methyl-CpG binding protein 2 (MECP2) cause Rett syndrome, a postnatal neurodevelopmental disorder that occurs in ~1/10,000 live female births. MeCP2 binds to methylated cytosines across genomic DNA and recruits various partners to regulate gene expression. MeCP2 has been shown to repress transcription in vitro and interacts with co-repressors such as the Sin3A and NCoR complexes. Based on these observations, MeCP2 has been largely considered as a repressor of transcription. However, a mouse model of RTT displays many down-regulated genes, and those same genes are up-regulated in a MECP2 duplication mouse model. Furthermore, TCF20, which has been associated with transcriptional activation, have recently been identified as a protein interactor of MeCP2. These data broaden the potential functions of MeCP2 as a regulator of gene expression. Yet, the molecular mechanisms underlying MeCP2-dependent gene regulation remain largely unknown. Here, using a human MECP2 gain-of-function Drosophila model, we screened for genetic modifiers of MECP2-induced phenotypes. Our approach identified several subunits of the Drosophila super elongation complex, a P-TEFb containing RNA polymerase II (RNA pol II) elongation factor required for the release of promoter-proximally paused RNA pol II, as genetic interactors of MECP2. We discovered that MeCP2 physically interacts with the SEC in human cells and in the mouse brain. Furthermore, we found that MeCP2 directly binds AFF4, the scaffold of the SEC, via the transcriptional repression domain. Finally, loss of MeCP2 in the mouse cortex caused reduced binding of AFF4 specifically on a subset of genes involved in the regulation of synaptic function, which also displayed the strongest decrease in RNA pol II binding in the genebody. Taken together, our study reveals a previously unrecognized mechanism through which MeCP2 regulates transcription, providing a new dimension to its regulatory role in gene expression.

MeCP2 duplication causes hyperandrogenism by upregulating LHCGR and downregulating RORα

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

Lack of MECP2 Gene Transcription on the Duplicated Alleles of Two Related Asymptomatic Females with Xq28 Duplications and Opposite X‐chromosome Inactivation Skewing

MeCP2 Interacts with the Super Elongation Complex to Regulate Transcription

MicroRNA-197 controls ADAM10 expression to mediate MeCP2’s role in the differentiation of neuronal progenitors

MECP2 and the biology of MECP2 duplication syndrome

Overexpression of methyl-CpG binding protein 2 impairs T(H)1 responses.

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus

MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex.

MECP2 duplication syndrome in a Chinese family

MeCP2 and neurodevelopmental disorders

MeCP2: Multifaceted Roles in Gene Regulation and Neural Development

MeCP2 links heterochromatin condensates and neurodevelopmental disease

Reversal of Social Recognition Deficit in Adult Mice with MECP2 Duplication Via Normalization of MeCP2 in the Medial Prefrontal Cortex

MECP2 duplication and mutations impair NSCs differentiation via miR-197 regulated ADAM10

The methyl-CpG-binding domain (MBD) is crucial for MeCP2's dysfunction-induced defects in adult newborn neurons.

MeCP2 Promotes Gastric Cancer Progression Through Regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 Signaling Pathways.

A Partial Loss of Function Allele of Methyl-Cpg-binding Protein 2 Predicts a Human Neurodevelopmental Syndrome.

Advance in research on MRCP2 duplication syndrome